Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Efficacy and safety of sibeprenlimab in IgA nephropathy: interim analysis of the China cohort in the phase 3 VISIONARY trial.
Journal: Clinical kidney journal
Published: April 01, 2026
Sibeprenlimab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial.
Journal: The New England journal of medicine
Published: November 10, 2025
A Pathway to High Quality Clinical Trials in IgA Vasculitis Nephritis: Meeting Proceedings From a Multiprofessional International Collaborative Workshop.
Journal: Kidney international reports
Published: October 30, 2025
Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority, phase 2b/c trial.
Journal: The Lancet. Infectious diseases
Published: September 11, 2025
Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial.
Journal: Kidney international reports
Published: June 06, 2025
Protecting households on exposure to newly diagnosed index multidrug-resistant tuberculosis patients: Study protocol for the PHOENIx phase 3 clinical trial.
Journal: Contemporary clinical trials
Published: February 19, 2025
Safety, pharmacokinetics, and early bactericidal activity of quabodepistat in combination with delamanid, bedaquiline, or both in adults with pulmonary tuberculosis: a randomised, active-controlled, open-label trial.
Journal: The Lancet. Infectious diseases
Published: April 26, 2024
Phase I Single Ascending Dose and Food Effect Study in Healthy Adults and Phase I/IIa Multiple Ascending Dose Study in Patients with Pulmonary Tuberculosis to Assess Pharmacokinetics, Bactericidal Activity, Tolerability, and Safety of OPC-167832.
Journal: Antimicrobial agents and chemotherapy
Published: May 23, 2023
Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial.
Journal: Antimicrobial agents and chemotherapy
Published: April 11, 2022
Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis.
Journal: Antimicrobial agents and chemotherapy
Published: November 29, 2021
Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update.
Journal: The European respiratory journal
Published: June 24, 2020
Last Updated: 09/26/2026